Has Amgen Already Won Its BPCIA Dispute With Sandoz?
Based on the U.S. Supreme Court's decision in Sandoz Inc. v. Amgen Inc.,[1] many have concluded that a biosimilar applicant has the "option' to disclose its application and manufacturing information to...To view the full article, register now.
Already a subscriber? Click here to view full article